ライフサイエンスコーパス: intravesical

1 Eligible patients received a single intravesical 75 mL dose of nadofaragene firadenovec (3 x

2 on bladder nociceptive responses induced by intravesical acetic acid infusion in rats.

3 Results: Intravesical administration of (18)F-labeled galactodend

4 AN activity were also suppressed (p<0.05) by intravesical administration of 2',3'-0-trinitrophenyl-AT

5 Intravesical administration of 25 and 50 muM oxo-M signi

6 Intravesical administration of 5 muM AMN alone did not a

7 der (10-40 cmH(2)O) was increased 22-100% by intravesical administration of 50 muM oxo-M.

8 Intravesical administration of BCG has been associated w

9 Correspondingly, in vivo intravesical administration of CCDC increased the number

10 tion was induced by three different stimuli: intravesical administration of either 0.25% acetic acid

11 eractivity that was significantly reduced by intravesical administration of either B1 (des-Arg(10)-Ho

12 or a novel method to treat bladder cancer by intravesical administration of LNP-formulated RNA duplex

13 Intravesical administration of Mycobacterium bovis bacil

14 Enhanced by polyamide surfactant Syn3, intravesical administration of rAd-IFNalpha2b results in

15 Intravesical administration of SNAP (2mM) which did not

16 Intravesical administration of targeted nanoparticles ca

17 lished tumor cell masses regressed following intravesical administration of the chemotherapeutic drug

18 Intravesical administration of the mAChR agonist oxotrem

19 These effects were blocked by intravesical administration of the mAChR antagonist atro

20 o be mediated by separate mechanisms because intravesical administration of the pannexin channel anta

21 Within several hours of intravesical administration of these agents, bladder tum

22 ing of human bladder cancer by topical (i.e. intravesical) administration of QD-conjugated anti-CD47.

23 Gemcitabine has substantial activity as an intravesical agent in BCG-refractory TCC and warrants fu

24 e efficacy of gemcitabine administered as an intravesical agent in patients with bacille Calmette-Gue

25 ty profile of gemcitabine administered as an intravesical agent in patients with transitional-cell ca

26 excellent candidate for investigation as an intravesical agent.

27 Up to 50% of patients treated with intravesical agents for superficial bladder cancer will

28 odal therapy (i.e., chemotherapy, radiation, intravesical agents) based on a handful of retrospective

29 ification of patients unlikely to respond to intravesical agents, in whom early cystectomy is advocat

30 e bladder cancer microenvironment through an intravesical agonistic antibody approach for the treatme

31 ive events) could be induced to discharge by intravesical alpha,beta-meATP (1 mM, 0.1 ml).

32 Intravesical application of alpha,beta-meATP (0.03-1 mM)

33 adder afferent recording preparation we show intravesical application of endogenous (5alpha-pregnan-3

34 dence favouring either an extravesical or an intravesical approach.

35 Intravesical bacille Calmette-Guerin (including a mainte

36 ere treated with transurethral resection and intravesical bacillus Calmette Guerin (BCG) therapy and

37 s the standard of care for patients who fail intravesical bacillus Calmette-Guerin (BCG) for nonmuscl

38 developed a systemic illness while receiving intravesical bacillus Calmette-Guerin (BCG) immunotherap

39 Combination therapy with intravesical bacillus Calmette-Guerin (BCG) plus IFN-alp

40 ith superficial bladder cancer refractory to intravesical bacillus Calmette-Guerin (BCG) therapy and

41 non-muscle-invasive BC patients according to intravesical Bacillus Calmette-Guerin (BCG) treatment st

42 cancer, the standard immunotherapy involves intravesical Bacillus Calmette-Guerin (BCG).

43 Data supports the use of intravesical Bacillus Calmette-Guerin (including a maint

44 The data support the use of intravesical bacillus Calmette-Guerin (including a maint

45 to treatment, 2250 patients (17.2%) received intravesical bacillus Calmette-Guerin, and 792 patients

46 ociated BCG infection who had never received intravesical BCG administration, an epidemiologic study

47 ational use of IFN-alpha in conjunction with intravesical BCG for bladder cancer immunotherapy.

48 gical basis for using it in conjunction with intravesical BCG for bladder cancer immunotherapy.

49 Intravesical BCG has been used successfully to treat sup

50 While intravesical BCG has remained the mainstay of therapy fo

51 hral resection of bladder tumour followed by intravesical BCG immunotherapy.

52 urvalumab (every 4 weeks for 13 cycles) plus intravesical BCG induction (weekly for 6 weeks) and main

53 ssociated BCG infection who had not received intravesical BCG instillation were selected and the sour

54 l bladder cancer refractory or intolerant to intravesical BCG therapy and refusing a cystectomy were

55 yelitis in a 79-year-old man 2.5 years after intravesical BCG therapy for bladder cancer.

56 ine if p53 status, assessed before and after intravesical BCG therapy, can predict clinical outcome i

57 Intravesical BCG therapy, including adequate induction B

58 ients, obtained immediately before and after intravesical BCG therapy.

59 volves complete transurethral resection with intravesical BCG therapy.

60 laining the pulmonary disease resulting from intravesical BCG treatment include a hypersensitivity re

61 multiple nonspecific beneficial effects, and intravesical BCG vaccine is currently the recommended tr

62 induction and maintenance immunotherapy with intravesical BCG vaccine or intravesical chemotherapy.

63 isk or high-risk disease can be treated with intravesical BCG, but many of these patients will experi

64 BCG isolates from patients who had received intravesical BCG.

65 Using intravesical bladder pressure recordings, we identify sp

66 Intravesical chemotherapeutic and immunotherapeutic agen

67 tte-Guerin, and 792 patients (6.1%) received intravesical chemotherapy (excluding receipt of a single

68 oral erdafitinib or investigator's choice of intravesical chemotherapy (mitomycin C or gemcitabine).

69 is cross-sectional study examines the use of intravesical chemotherapy after transurethral resection

70 tor (FGFR) tyrosine kinase inhibitor, versus intravesical chemotherapy in patients with high-risk NMI

71 Erdafitinib prolonged RFS compared with intravesical chemotherapy in patients with papillary-onl

72 for low-risk papillary NMIBC, and induction intravesical chemotherapy is an option for patients with

73 As an alternative, perioperative intravesical chemotherapy is recommended for low-risk pa

74 decrease the recurrence or progression rate, intravesical chemotherapy or immunotherapy is also used.

75 Combination intravesical chemotherapy, targeted therapy, and drug de

76 mized clinical trial showing the benefits of intravesical chemotherapy.

77 munotherapy with intravesical BCG vaccine or intravesical chemotherapy.

78 Intravesical chitosan/IL-12 is a well-tolerated, effecti

79 nd no systemic absorption in the first human intravesical clinical trial.

80 dder and was observed in a patient receiving intravesical combination therapy.

81 Combination intravesical cretostimogene and systemic pembrolizumab d

82 d the potential synergistic efficacy between intravesical cretostimogene and systemic pembrolizumab i

83 ed a phase 1b study using the combination of intravesical cretostimogene grenadenorepvec (oncolytic s

84 Thirty-five patients were treated with intravesical cretostimogene with systemic pembrolizumab.

85 xcitation of bladder reflexes in response to intravesical cytisine (100 muM) is blocked by systemic a

86 STING agonist VB-85247 for treating NMIBC by intravesical delivery as a strategy to provide a sustain

87 mice with orthotopic bladder cancer through intravesical delivery of anti-CD40 agonist antibodies dr

88 Intravesical delivery of LNP-dsP21-322-2'F into mouse bl

89 -322-2'F) into lipid nanoparticles (LNP) for intravesical delivery.

90 Intravesical docetaxel exhibited minimal toxicity and no

91 bladder cancer model, we found that a single intravesical dose of combined BCG and beta-glucan immuno

92 Bladder cancer treatment via intravesical drug administration achieves reasonable sur

93 of OxoM (0.01-5 microg/kg) did not mimic the intravesical effects on voiding frequency.

94 s Calmette-Guerin (BCG) shortage, sequential intravesical gemcitabine and docetaxel has been increasi

95 Intravesical gemcitabine has shown some promising result

96 Eligible patients received two courses of intravesical gemcitabine twice weekly at a dose of 2,000

97 r tumor, patients received either sequential intravesical gemcitabine, 1 g, and docetaxel, 37.5 mg, o

98 Intravesical gemcitabine, at doses up to 2 g/wk, is well

99 ted in TRPV1-/- mice in which sensitivity to intravesical hydrochloric acid (50 mm) and capsaicin (10

100 In clinical practice, intravesical IFN-alpha 2B (50 million units (MU)/dose) w

101 , mucoadhesive polysaccharide, could improve intravesical IL-12 delivery and provide an effective and

102 Unfortunately, intravesical IL-12 did not show antitumor efficacy in a

103 rithm was capable of capturing and stitching intravesical images with different sweeping patterns.

104 (NMIBC) is a highly recurrent tumor despite intravesical immunotherapy instillation with the bacillu

105 Intravesical immunotherapy using Bacille Calmette-Guerin

106 d urinary bladders underwent a new method of intravesical implantation of the transplant ureter.

107 Intravesical infusion of 0.1% acetic acid induced bladde

108 asation in the bladder or urethra induced by intravesical infusion of 0.25% acetic acid.

109 vely new drugs in the field, administered as intravesical injection and instillation, respectively.

110 These effects were blocked by intravesical injection of 5 muM atropine methyl nitrate

111 gement, medications, intravaginal pessaries, intravesical injection of botulinum toxin, percutaneous

112 rats bearing either bladder cancer (*IUdR by intravesical injection), brain gliosarcomas (intratumora

113 Infections were induced in female mice by intravesical inoculation with Escherichia coli, and the

114 ladder and kidney infections after receiving intravesical inoculation with uropathogenic Escherichia

115 Intravesical instillation of Ad5CMV-p53 is safe, feasibl

116 ly induces an inflammatory reaction, such as intravesical instillation of Bacillus Calmette-Guerin.

117 Intravesical instillation of bacterial lipopolysaccharid

118 on control anaesthetized rats revealed that intravesical instillation of bradykinin activated the mi

119 For superficial disease, intravesical instillation of chemotherapeutic agents aft

120 al resection of the tumor with perioperative intravesical instillation of chemotherapy strongly sugge

121 Intravesical instillation of compound 48/80 increased me

122 Intravesical instillation of small interfering RNA-conta

123 ow available, including extended release and intravesical instillation.

124 ction BCG therapy, was defined as at least 5 intravesical instillations of BCG within 70 days from BC

125 On a 28-day cycle, intravesical instillations of INGN 201 (Ad5CMV-p53) were

126 ients were randomly assigned for 16 adjuvant intravesical instillations with KLH after preimmunizatio

127 ients were randomly assigned for 11 adjuvant intravesical instillations with MM.

128 enrolled to receive 2 induction courses (12 intravesical instillations) of BCG without maintenance t

129 Most importantly, intravesical K(+) causes and is required to maintain bla

130 that in the presence of a leaky urothelium, intravesical K(+) sensitizes bladder afferents and enhan

131 Treatments include intravesical maintenance Bacillus Calmette-Guerin (mBCG)

132 The intravesical method has been validated and is considered

133 lume needed to accurately measure IAP by the intravesical method in children is 3 mL.

134 stillation volume for IAP measurement by the intravesical method in children.

135 Electromotive intravesical mitomycin C as well as local microwave hype

136 The intervention group received intravesical MMC (40 mg/40 mL) three times a week for 2

137 Intravesical nadofaragene firadenovec was efficacious, w

138 nergic agonist treatment with progression to intravesical onabotulinumtoxinA therapy or neuromodulati

139 cell infiltration was broadly induced after intravesical oncolytic immunotherapy, the formation, enl

140 view and meta-analysis is to determine if an intravesical or extravesical anastomosis in kidney trans

141 Conversely, intravesical or systemic administration of recombinant C

142 Intravesical or transdermal electrical stimulation, sacr

143 l role in the control of micturition because intravesical perfusion of apyrase or the ecto-ATPase inh

144 Intravesical perfusion of the ATP diphosphohydrolase apy

145 ual dimorphic changes; in females, increased intravesical pressure at micturition and downregulations

146 d videocystometry in rodents, which combines intravesical pressure measurements with X-ray-based fluo

147 ability to maintain volumetric capacity and intravesical pressure resulting in renal deterioration.

148 lectrical triggering system, which leverages intravesical pressure to produce electricity.

149 dysfunctional (decompensated), showing high intravesical pressure, large residual urine volume, and

150 multiphoton microscopy, we measured ex vivo intravesical pressure, mechanical compliance, wall thick

151 bladder cancer, our results indicate that an intravesical pressure-driven system in the bladder gener

152 Prostatic ultrasound measures such as the intravesical prostatic protrusion may be useful in couns

153 either T(1) mapping was repeated after brief intravesical PS exposure or the animals were sacrificed

154 HG BCG-refractory or relapsed NMIBC received intravesical rAd-IFNalpha/Syn3 (randomly assigned 1:1 to

155 der distension (UBD) in rats pretreated with intravesical resiniferatoxin (RTX, 10(-7)M).

156 : STING agonist VB-85247 administered by the intravesical route achieves prolonged tumor regression,

157 The intravesical route is still in the investigational phase

158 e results of our study provide evidence that intravesical RTX reduces the effects of viscerovisceral

159 ometrograms under urethane anesthesia during intravesical saline infusion exhibited intercontraction

160 CF) (1-100 mum, intravesically), or by using intravesical small interfering RNA, increased the interv

161 eb response system to receive four cycles of intravesical TAR-200 (225 mg gemcitabine) plus intraveno

162 Multiple intravesical therapies have been used in this BCG failur

163 Response rates to second-line intravesical therapies range from 20% to 40%.

164 rethral resection of the tumors, followed by intravesical therapy (IT), which comprises a direct inst

165 nvasive tumors permits appropriate timing of intravesical therapy and radical cystectomy.

166 t for non-muscle-invasive bladder cancer and intravesical therapy can further improve oncological out

167 cell bladder carcinoma who experienced prior intravesical therapy failure were studied.

168 DNA into the bladder epithelium, and a novel intravesical therapy for BCG-unresponsive non-muscle-inv

169 cillus Calmette-Guerin is the most effective intravesical therapy for the treatment of superficial bl

170 diotherapy alone does not appear superior to intravesical therapy in NMIBC, at least one series with

171 Although Bacillus Calmette-Guerin (BCG) intravesical therapy is a standard treatment for bladder

172 on, nested variant, and other rare variants, intravesical therapy is an option based on standard risk

173 Intravesical therapy is utilized both as a one-time peri

174 arch has focused on improving and optimizing intravesical therapy to reduce tumor recurrence and prog

175 All patients who receive intravesical therapy with bacille Calmette-Guerin should

176 ndard therapeutic resection (with or without intravesical therapy), the superficial bladder tumor rec

177 thelial cell carcinoma (early cystectomy vs. intravesical therapy).

178 eated with endoscopic resection and adjuvant intravesical therapy, depending on the risk classificati

179 Intravesical treatment is used for carcinoma in situ and

180 CD40 and Fcy receptors, we demonstrate that intravesical treatment with a fully human, Fc-enhanced a

181 lity barrier (BPB) are the main obstacles to intravesical treatments for bladder diseases, and is evi

182 hotopic bladder tumors were cured after four intravesical treatments with chitosan/IL-12.

183 urable and provided complete protection from intravesical tumor rechallenge.

184 in 16 piglets (32 kidneys) by unroofing the intravesical ureter and subsequently instilling a broth

185 Thus, intravesical vaccination with one or more UPEC antigens

186 Intravesical vanilloid (capsaicin or resiniferatoxin) ad

187 studies have demonstrated the feasibility of intravesical viral-mediated gene therapy.